A fast-spreading Omicron variant that causes milder illness compared with previous versions of the coronavirus has fueled the view that COVID-19 poses less of a risk than in the past.
In which case, some ask, why go to great lengths to prevent getting infected now, since everybody will be exposed to the virus sooner or later?
Here is why experts say it is not time to be complacent about Omicron:
YOU COULD STILL BECOME VERY ILL
Research has indicated that Omicron may be more likely to lead to an asymptomatic case of COVID-19 than prior variants. For those who do have symptoms, a higher proportion experience very mild illness, such as sore throat or runny nose, without the breathing difficulties typical of earlier infections.
But the extraordinary spread of Omicron in many countries means that in absolute numbers, more people will experience severe disease. In particular, recent data from Italy and Germany show that people who are not vaccinated are far more vulnerable when it comes to hospitalization, intensive care and death.
"I agree that sooner or later everyone will be exposed, but later is better," said virus expert Michel Nussenzweig of Rockefeller University. "Why? Because later we will have better and more available medicines and better vaccines."
YOU COULD INFECT OTHERS
You might become only mildly ill, but you could pass the virus to someone else at risk for critical illness, even if you have antibodies from a prior infection or from vaccination, said Akiko Iwasaki, who studies viral immunology at Yale University.
OMICRON'S LONG-TERM EFFECTS ARE UNKNOWN
Infections with earlier variants of the coronavirus, including mild infections and "breakthrough" cases after vaccination, sometimes caused the lingering, debilitating long-haul COVID syndrome. "We have no data yet on what proportion of infections with Omicron... end up with Long COVID," Iwasaki said. "People who underestimate Omicron as 'mild' are putting themselves at risk of debilitating disease that can linger for months or years."
Also unclear is whether Omicron will have any of the "silent" effects seen with earlier variants, such as self-attacking antibodies, sperm impairments and changes in insulin-producing cells.
MEDICATIONS ARE IN SHORT SUPPLY
Omicron treatments are so limited that doctors must ration them. Two of the three antibody drugs used during past COVID-19 waves are ineffective against this variant. The third, sotrovimab, from GlaxoSmithKline, is in short supply, as is a new oral antiviral treatment called Paxlovid, from Pfizer Inc, that appears effective against Omicron. If you get sick, you might not have access to treatments.
HOSPITALS ARE FILLING UP
In fully vaccinated and boosted individuals without underlying medical conditions, Omicron "will not do too much damage," said David Ho, professor of microbiology and immunology at Columbia University. Still, the fewer infections, the better, especially now, "when the hospitals are already overwhelmed, and the peak of Omicron wave is yet to come" for most of the United States, Ho said.
Due to record numbers of infected patients, hospitals have had to postpone elective surgeries and cancer treatments. And during past surges, overwhelmed hospitals have been unable to properly treat other emergencies, such as heart attacks.
MORE INFECTIONS MEAN MORE NEW VARIANTS
Omicron is the fifth highly significant variant of the original SARS-COV-2, and it remains to be seen if the ability of the virus to mutate further will slow down.
High infection rates also give the virus more opportunities to mutate, and there's no guarantee that a new version of coronavirus would be more benign than its predecessors. "SARS-CoV-2 has surprised us in many different ways over the past two years, and we have no way of predicting the evolutionary trajectory of this virus," Ho said.
INFECTION NOW MIGHT NOT PREVENT REINFECTION LATER
Variants evolve to evade people's immunity to earlier variants. How well Omicron antibodies will protect against future variants is unclear. Early COVID-19 survivors had antibodies that could neutralize the original virus but were less effective against variants, the U.S. Centers for Disease Control and Prevention said, and people who were only mildly ill were less likely to be able to neutralize future variants compared to survivors of severe disease. Like the common-cold coronaviruses that cause milder upper respiratory infections, Omicron "will not induce lasting immunity," Dr. Peter Hotez, a vaccine researcher at Baylor College of Medicine, predicted in a tweet on Thursday.
Reuters
Fri Jan 14 2022
Research has indicated that Omicron may be more likely to lead to an asymptomatic case of COVID-19 than prior variants. - REUTERS
HAWANA diharap perjuang caruman KWSP, PERKESO wartawan sambilan
Walaupun berstatus wartawan sambilan, mereka juga ialah kelompok penting dalam dunia kewartawanan hari ini.
Niaga AWANI: Prestasi Bursa Malaysia setakat 13 Mei 2024
Bursa Malaysia dijangka mencatatkan dagangan dalam julat kecil dan mengalami tidak banyak perubahan susulan kenaikan baru-baru ini, sejajar dengan ekuiti global, kata peniaga.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Prestasi ringgit setakat 13 Mei 2024
Ringgit dijangka diniagakan dalam keadaan berhati-hati berbanding dolar Amerika Syarikat (AS) minggu ini memandangkan pelabur mencari petunjuk baharu daripada data ekonomi yang lebih signifikan.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Ringgit dijangka berhati-hati minggu ini berbanding dolar AS
Ketua Ahli Ekonomi Bank Muamalat Malaysia Bhd Dr Mohd Afzanizam Abdul Rashid berkata peserta pasaran akan meneliti data utama, termasuk data AS mengenai Indeks Harga Pengeluar, Indeks Harga Pengguna dan jualan runcit, untuk membina keyakinan mereka.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Niaga hadapan MSM dijangka didagangkan mendatar minggu depan
Secara mingguan, kontrak bulan semerta bagi Mei 2024 turun RM37 kepada RM3,853 satu tan, Jun 2024 susut RM27 kepada RM3,843 satu tan dan Julai 2024 adalah lebih rendah sebanyak RM35 kepada RM3,809 satu tan.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Bursa Malaysia dijangka mencatatkan dagangan kecil
Naib Presiden Penyelidikan Ekuiti Rakuten Trade Sdn Bhd Thong Pak Leng berkata indeks dijangka turun naik dalam julat 1,600 hingga 1,620 minggu ini.
#NiagaAWANI
#NiagaAWANI
Niaga AWANI: Seimbangkan strategi pelaburan ketika pasaran di paras tertinggi
Ketua Penyelidikan Pelaburan, UOB Kay Hian Wealth Advisors, Mohd Sedek Jantan kongsi tentang bagaimana untuk mengimbangkan strategi pelaburan ketika pasaran berada pada paras tertinggi.
#NiagaAWANI
#NiagaAWANI
Putin tukar Menteri Pertahanan, Shoigu dengan ahli ekonomi
Tugas baharu Sergei Shoigu ialah sebagai Setiausaha Majlis Keselamatan Rusia.
Kenaikan 224 peratus cukai taksiran relevan - MPAJ
Kenaikan cukai taksiran dilihat sangat wajar jika dibandingkan dengan tempoh kali terakhir MPAJ menyediakan Senarai Nilaian Baharu pada 1997.
Niaga AWANI: Apakah prestasi ekonomi suku pertama?
Ekonomi suku pertama akan diumum minggu ini. Apakah jangkaan semasa berdasarkan perkembangan antarabangsa dan tempatan? Bagaimana pengeluaran akaun tiga kwsp memainkan peranan dan adakah rasionalisasi subsidi akan beri impak besar?
#NiagaAWANI
#NiagaAWANI
COVID-19 terkawal tetapi virus akan terus ada bersama kita - KKM
Kebanyakan kes COVID-19 yang dilaporkan mengalami gejala ringan dan tidak memerlukan rawatan di hospital.
COVID-19: Kes aktif varian Omicron bergejala ringan - Pakar perubatan
Beliau berkata kes COVID-19 dijangka berkurangan selepas satu bulan berdasarkan pemerhatian trend jangkitan virus oleh KKM.
COVID-19: Kes meningkat kepada 12,757 pada ME49/2023
Walaupun terdapat peningkatan kes COVID-19, keadaan di Malaysia masih terkawal dan tidak membebankan fasiliti kesihatan sedia ada.
COVID-19: Kes jangkitan meningkat kepada 2,305 minggu lalu, 21 varian Omicron
Daripada jumlah itu, terdapat 20 kes Variant of Concern (VOC) dan satu kes Variant of Interest (VOI).
COVID-19: Qatar kesan kes pertama varian baharu EG.5
Qatar mengesan kes pertama varian baharu COVID-19 dikenali EG.5 di negara itu, kata Kementerian Kesihatan Awam pada Khamis.
Saintis seru rakyat UK pakai pelitup muka ekoran varian baharu "Eris"
Saintis menggesa orang ramai di United Kingdom kembali memakai pelitup muka di tengah-tengah kebimbangan "mutasi" subvarian Omicron, "Eris" yang kini menyumbang satu daripada 10 kes di negara itu.
Berita antarabangsa pilihan sepanjang hari ini
Antara pelbagai berita luar negara yang disiarkan di Astro AWANI, berikut adalah yang paling menjadi tumpuan sepanjang Selasa, 18 April 2023.
COVID-19: Indonesia kesan tujuh kes Arcturus setakat ini
Indonesia mengesan lima kes baharu subvarian Omicron, Arcturus, menjadikan jumlah keseluruhan kepada tujuh kes setakat semalam.
Kes COVID-19 dalam negara masih terkawal - Dr Zaliha
Kes COVID-19 di dalam negara ini masih lagi terkawal meskipun berlaku sedikit peningkatan kebelakangan ini dan rakyat tidak perlu panik, kata Menteri Kesihatan Dr Zaliha Mustafa.
Vaksin COVID-19: Australia lancar dos penggalak kelima
Keputusan itu memperluaskan kelayakan suntikan dos penggalak merangkumi kira-kira 14 juta orang yang akan ditawarkan vaksin.